Search

Displaying results 5491 - 5500 of 7058 in total
  1. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  2. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).

  3. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    Erdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.

  4. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It i...

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.

  7. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. … It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc.

  8. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  9. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

  10. Drug

    Asimadoline

    go.drugbank.com/drugs/DB05104
    Investigational

    Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. … It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.